Foghorn Therapeutics CFO Allan Reine resigns effective Jan 16, 2024

Foghorn Therapeutics Inc.

CFO Allan Reine resigns to pursue other opportunity; effective Jan 16, 2024.
Departure not due to any disagreement with company's operations, policies, or financial controls.
Company has commenced formal search for a successor; CEO thanked Reine for his leadership.
Dr. Reine's last full-time day will be January 16, 2024.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Allan Reine

Chief Financial Officer

FHTX · Foghorn Therapeutics Inc.

Effective: 2024-01-16
Filed: January 3, 2024, 6:59 PM ET

Allan Reine, M.D. notified Foghorn Therapeutics Inc. (the "Company") of his decision to resign as Chief Financial Officer, effective January 16, 2024, to pursue other opportunities.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Allan Reine resigned as Chief Financial Officer at Foghorn Therapeutics Inc..

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

Allan Reine, M.D. notified Foghorn Therapeutics Inc. (the "Company") of his decision to resign as Chief Financial Officer, effective January 16, 2024, to pursue other opportunities.

View on SEC.gov

Foghorn Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001628280-24-000199

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.